We read with interest the letter ‘the dilemmas of breast cancer treatment and increased fracture risk’ by Malik [1] and thank him to his attention to our article [2].

We would like to add some commentaries. As mentioned in the initial article describing the baseline characteristics of the patients of our cohort [3], 920 women with breast cancer were examined between January 2006 and January 2009. Among them, 615 women with a tumor expressing estrogen receptor were treated by aromatase inhibitor (AI) therapy. 530 women without bone metastasis agreed to have an osteoporosis assessment within the first 3 months of AI therapy and finally 497 women without bone medication were included. Among …